265 related articles for article (PubMed ID: 22956062)
21. Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer.
Mamtani A; Patil S; Stempel M; Morrow M
Ann Surg Oncol; 2017 Aug; 24(8):2182-2188. PubMed ID: 28429197
[TBL] [Abstract][Full Text] [Related]
22. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
[TBL] [Abstract][Full Text] [Related]
23. Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial.
Canavese G; Bruzzi P; Catturich A; Tomei D; Carli F; Garrone E; Spinaci S; Lacopo F; Tinterri C; Dozin B
Ann Surg Oncol; 2016 Aug; 23(8):2494-500. PubMed ID: 26975739
[TBL] [Abstract][Full Text] [Related]
24. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
[TBL] [Abstract][Full Text] [Related]
25. Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
Majid S; Rydén L; Manjer J
BMC Cancer; 2019 Jun; 19(1):626. PubMed ID: 31238899
[TBL] [Abstract][Full Text] [Related]
26. Sentinel lymph node biopsy in breast cancer New indications and our experience.
Zanghì G; Rinzirillo NM; Caponnetto AM; Vecchio R; Catania V; Leanza V
Ann Ital Chir; 2015; 86():508-12. PubMed ID: 26898363
[TBL] [Abstract][Full Text] [Related]
27. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
[TBL] [Abstract][Full Text] [Related]
28. Survival analysis of early-stage breast cancer patients undergoing axillary lymph node dissection and sentinel lymph node dissection.
Nayyar A; Strassle PD; Shen MR; Black JA; Gallagher KK; McGuire KP
Am J Surg; 2018 Oct; 216(4):706-712. PubMed ID: 30060915
[TBL] [Abstract][Full Text] [Related]
29. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
[TBL] [Abstract][Full Text] [Related]
30. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
[TBL] [Abstract][Full Text] [Related]
31. Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer.
Kapoor NS; Shamonki J; Sim MS; Chung CT; Giuliano AE
Ann Surg Oncol; 2013 Aug; 20(8):2576-81. PubMed ID: 23468047
[TBL] [Abstract][Full Text] [Related]
32. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
[TBL] [Abstract][Full Text] [Related]
33. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
[TBL] [Abstract][Full Text] [Related]
34. Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes.
Schrenk P; Tausch C; Wölfl S; Bogner S; Fridrik M; Wayand W
Am J Surg; 2008 Aug; 196(2):176-83. PubMed ID: 18513692
[TBL] [Abstract][Full Text] [Related]
35. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
36. Axillary node staging for microinvasive breast cancer: is it justified?
Lyons JM; Stempel M; Van Zee KJ; Cody HS
Ann Surg Oncol; 2012 Oct; 19(11):3416-21. PubMed ID: 22576061
[TBL] [Abstract][Full Text] [Related]
37. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
[TBL] [Abstract][Full Text] [Related]
38. The evolution of the sentinel node procedure in the treatment of breast cancer.
Tvedskov TF
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
[TBL] [Abstract][Full Text] [Related]
39. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.
Goyal A; Newcombe RG; Chhabra A; Mansel RE
Ann Surg Oncol; 2008 Jan; 15(1):262-7. PubMed ID: 17879117
[TBL] [Abstract][Full Text] [Related]
40. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system.
Huang TW; Kuo KN; Chen KH; Chen C; Hou WH; Lee WH; Chao TY; Tsai JT; Su CM; Huang MT; Tam KW
Int J Surg; 2016 Oct; 34():73-80. PubMed ID: 27562691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
